ArticleFrontiers in artificial intelligence2026
Baseline mood and non-motor symptom burden are associated with cognitive progression in Parkinson's disease: an interpretable follow-up cohort analysis with separate neuroimaging, molecular, and digital analyses in independent samples.
Article in Frontiers in artificial intelligence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinically useful artificial intelligence and machine-learning studies in healthcare require interpretable features, internal validation, and explicit boundaries between primary inference and external context. Among 1,612 baseline Parkinson's Progression Markers Initiative (PPMI) participants, 1,439 had evaluable post-baseline cognition and contributed 5,909 records through Year 5. Composite cognitive progression occurred in 720 participants (50.0%). Each standard deviation increase in baseline mood/non-motor burden was associated with higher odds of progression (adjusted odds ratio 1.37, 95% confidence interval 1.20-1.55). The 1,000-resample participant bootstrap interval was 1.20-1.57, and estimates were stable across 1- to 5-year windows (odds ratios 1.35-1.41). In 10 repetitions of stratified 5-fold cross-validation, adding composite burden to clinical covariates produced a modest increase in mean area under the receiver operating characteristic curve from 0.665 to 0.682. We interpreted the PPMI result alongside separate neuroimaging, transcriptomic, and digital analyses in other samples and specified a future same-participant study; the separate analyses were not used for participant-level integration or validation. In the small resting-state functional magnetic resonance imaging cohort, most static and dynamic comparisons did not survive false-discovery-rate correction; two threshold-specific network-based-statistic components were retained as exploratory hypotheses. Molecular rankings were consistent with previously reported Parkinson's disease biology, while wearable and voice datasets demonstrated feasibility for the source-task only. Baseline mood/non-motor assessment may support future risk-enrichment research, but the limited cross-validated increment, absence of external clinical validation, and lack of participant-matched multimodal data preclude clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.